Jungers P, Devillier P, Salomon H, Cerisier J E, Courouce A M
Department of Nephrology, Hôpital Necker, Paris, France.
Lancet. 1994 Sep 24;344(8926):856-7. doi: 10.1016/s0140-6736(94)92829-0.
Natural interleukin-2 at low dose has been reported to overcome the non-responsiveness of patients with chronic uraemia to hepatitis B vaccine. Therefore, we revaccinated 52 previous such non-responders (24 on maintenance dialysis) with 20 micrograms of recombinant preS2-containing hepatitis B vaccine with human recombinant interleukin-2 (1 MU) or placebo (randomly allocated). Seroconversion rates (74 vs 80%, respectively) and proportion of patients who elicited anti-HBs titres of 10 mlU/mL or more (56 vs 68%) were similar in both groups. Our results do not confirm local injection of interleukin-2 as an effective immunoadjuvant to hepatitis B vaccine in uraemic patients.
据报道，低剂量的天然白细胞介素-2可克服慢性尿毒症患者对乙型肝炎疫苗的无反应性。因此，我们用20微克含前S2重组乙型肝炎疫苗加人重组白细胞介素-2（1MU）或安慰剂（随机分配）对52例先前无反应者（24例维持性透析患者）进行再次接种。两组的血清转化率（分别为74%和80%）以及抗-HBs滴度达到10 mIU/mL或更高的患者比例（56%和68%）相似。我们的结果不支持局部注射白细胞介素-2作为尿毒症患者乙型肝炎疫苗的有效免疫佐剂。
